#USA #Barcelona #biotech #Clinical Trials #Veeva Basics

Veeva Basics Revolutionizes Biotech Operations

In the ever-evolving world of biotechnology, efficiency and reliability are key to success. Veeva Systems (NYSE: VEEV) recently made headlines by announcing that over 75 emerging biotech companies have started leveraging Veeva Basics to enhance their operational efficiency, particularly in clinical, regulatory, and quality areas. These applications are designed to help biotechs streamline their processes and reduce costs, ultimately allowing them to focus on innovation and development.

What is Veeva Basics?

Veeva Basics is a software suite specifically tailored to meet the unique needs of rapidly growing biotech firms. It offers pre-configured, validated solutions that can be swiftly deployed, regardless of the organization’s size. The program assists companies in moving from disparate basic tools to comprehensive, cutting-edge solutions that support sustainable growth.

The suite is built on the robust Vault platform, enabling clients to scale their technological infrastructure as they expand. Among its newly minted offerings are:

• - Veeva CTMS Basics: A clinical trial management system that oversees milestones, monitoring, enrollment, issue resolution, and site communications.
• - Veeva Submissions Publishing Basics: This application provides support for creating, publishing, and submitting regulatory applications from a single unified system.

Advantages of Veeva Basics

According to Steve Harper, the General Manager of Veeva Basics, the growing adoption of this software in North America and Europe signifies a significant shift in the industry. Companies deploying Veeva Basics are expected to save time, money, and effort while keeping pace with regulatory requirements.

Harper asserts, “Our approach to providing pre-configured and validated solutions for rapid implementation is gaining traction. We continue to include new clinical and regulatory solutions to meet the needs of high-growth companies.” This flexible and comprehensive framework allows biotech firms to stay updated with the latest industry features.

Customer Feedback

Feedback from biotech leaders further underscores the positive impact of Veeva Basics. Dr. Ian Hodgson, COO of Corbus Pharmaceuticals, shared, “I believe Veeva Basics is revolutionary as it gives smaller biotechs access to the same modern, connected applications that large organizations typically enjoy. I trust that as our company grows, Veeva's platform will meet our evolving needs.”

Similarly, Joe Thornton, Associate Director of Clinical Operations at Scancell, emphasized the importance of Veeva eTMF Basics in maintaining control over data and processes. “Having an industry-leading solution with best-in-class practices as a foundation for our trials will enhance our speed and innovation as we develop new immunotherapies,” he noted.

Lastly, Rebecca Deng, Ph.D., Associate Director of Regulatory Affairs & Quality Control Systems at Terns Pharmaceuticals, affirmed the value of Veeva’s global support and training, explaining that it helps them maximize the benefits of Veeva's industry solutions. “The straightforward startup and validation process has generated significant time and resource savings,” she stated.

Conclusion

With the rapid progression in biotechnology and increasing demands for efficiency, Veeva Basics is positioning itself as an essential tool for companies striving for success. As more firms adopt these innovative solutions, it’s clear that Veeva Systems is paving the way for the future of biotech operations. For additional details, potential clients can visit veeva.com/VeevaBasics.